MDSpire - Summary
From the Journals

Trial Tests Single-Day TRD Treatment 

Randomized trial found more than half of treated patients achieved remission within 8 days.

Share

In a phase 2b randomized clinical trial, inhaled mebufotenin (GH001) demonstrated significant efficacy in treating treatment-resistant depression, with over half of the 81 enrolled patients achieving remission by day 8. The trial, conducted across 16 sites in Europe, showed a mean reduction of 15.2 points in depression severity for those receiving GH001, compared to no changes in the placebo group. Although beneficial, most patients required additional treatments to maintain remission, and adverse reactions were mild to moderate. Further research is needed to understand long-term outcomes.

Original Source(s)

Trial Tests Single-Day TRD Treatment 

  • by Andrea Surnit

  • March 26, 2026

Related Content

GLP-1 Drugs Examined in Psychiatric Outcomes

Researchers evaluate mental health trajectories with antidiabetic therapies in patients with depression or anxiety.

Medical Oddities: When Men Face Catcalling

Cooking, catcalling, and colon swaps—medicine keeps things interesting.

Moral Distress Associated With Physician Burnout

Researchers link distress to burnout, professional fulfillment, and intent to leave or reduce clinical hours.